Using data from the Global Burden of Disease 2021, researchers applied advanced statistical techniques, including Joinpoint regression and random forest modeling, to dissect the intricate relationships between PAH incidence and the prevalence of various hemolytic disorders. The findings were striking: while PAH age-standardized incidence rates (ASIR) modestly increased worldwide from 0.50 to 0.52 per 100,000 people between 1990 and 2021, the strongest predictor of this rise was not socio-demographic factors but hemolysis-associated conditions.

Specifically, variants of glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic trait affecting red blood cell stability, emerged as the top contributor to PAH incidence. Other hemoglobinopathies and hemolytic anemias of uncertain origin also displayed robust positive correlations with PAH rates. Intriguingly, vitamin A deficiency—known to impact red blood cell health—was another critical and previously underappreciated driver identified in this model, surpassing the influence of the socio-demographic index and sex differences.

The employment of random forest regression explained an impressive 73% of the variance in PAH incidence globally, underscoring the potency of hemolytic disorder prevalence as a predictive factor. Temporal trends further reinforced these conclusions, revealing parallel increases in hemolytic disorder prevalence and PAH incidence, with a high correlation coefficient of 0.76.

In addition to genetic and nutritional contributors, the study’s exploratory investigations hinted that environmental exposures to natural products could be an underrecognized influence on the hemolytic burden, potentially exacerbating PAH risks in exposed populations. This novel insight opens new avenues for research into environmental triggers of hemolysis-mediated cardiovascular pathology.

Looking ahead, sophisticated Bayesian age-period-cohort models project a continued rise in both PAH burden and hemolytic disease prevalence through 2050. These projections predict that PAH incidence will climb to 0.57 per 100,000 people, while hemolytic disorder prevalence is expected to escalate from approximately 27,760 to over 31,800 cases per 100,000 globally. Such trends highlight the urgent need for public health strategies that prioritize the identification, prevention, and management of hemolysis-associated conditions.

This landmark study fundamentally reorients the understanding of PAH epidemiology by establishing hemolytic disorders—not just traditional socio-demographic factors—as key and modifiable drivers of disease burden. It advocates for a paradigm shift in global health policy to incorporate hemolytic disorder screening and treatment into pulmonary hypertension prevention programs, potentially mitigating a significant and growing cause of cardiovascular morbidity worldwide.

Published in the peer-reviewed journal Future Integrative Medicine, these findings promise to catalyze further translational and clinical research, illuminating the path toward innovative therapies personalized to hemolytic disease profiles. As the global healthcare community grapples with the rising tide of PAH, this work underscores the critical intersection of genetics, nutrition, environmental factors, and cardiovascular health.

Subject of Research: Hemolysis-associated disorders and their contribution to pulmonary arterial hypertension incidence
Article Title: Hemolysis-associated Disorder and Natural Product Exposures: Underrecognized Drivers of an Escalating Global Pulmonary Arterial Hypertension Burden—An Ecological Study of 204 Countries and Territories
News Publication Date: June 18, 2026
Web References: http://dx.doi.org/10.14218/FIM.2026.00004
Keywords: Pulmonary arterial hypertension, hemolysis, G6PD deficiency, hemoglobinopathies, vitamin A deficiency, global health, epidemiology

G6PD deficiency, a hereditary enzymatic disorder affecting millions worldwide, primarily disrupts the redox balance within cells by impairing the pentose phosphate pathway. This pathway is pivotal for the generation of nicotinamide adenine dinucleotide phosphate (NADPH), which in turn plays a protective role in mitigating oxidative stress. The deficiency spuriously lowers cellular antioxidant capability, heightening vulnerability to oxidative damage, particularly in red blood cells. It is well-established that G6PD deficiency precipitates acute hemolytic anemia under certain stressors such as infection, certain medications, or ingestion of fava beans. However, this new research probes well beyond these immediate hematological consequences to investigate how G6PD deficiency might modulate susceptibility to a broad spectrum of pediatric diseases.

Utilizing a robust cohort design, the investigators harnessed data from thousands of pediatric patients, employing both retrospective and prospective methodologies to evaluate disease occurrence in G6PD-deficient populations compared to non-deficient controls. The research team applied advanced genomic and proteomic tools alongside thorough clinical phenotyping, thus affording a multidimensional perspective on disease vulnerability. Their approach facilitated an unprecedented examination of whether G6PD-associated oxidative imbalances might compromise immune defenses or alter inflammatory responses, thereby influencing the risk and severity of infectious and chronic diseases in childhood.

Notably, one of the most striking findings of this study was the significantly higher incidence of respiratory infections, particularly viral upper respiratory tract infections and pneumonia, among children with G6PD deficiency. The investigators hypothesize that impaired NADPH production limits the ability of phagocytes, such as neutrophils and macrophages, to generate reactive oxygen species essential for pathogen clearance, effectively dampening frontline immune defenses. This mechanistic insight aligns with prior knowledge about the respiratory system’s vulnerability to oxidative injury and positions G6PD deficiency as a critical modifier of infection risk in pediatric cohorts.

In addition to respiratory pathogens, the study documented an augmented incidence of enteric infections and gastrointestinal disturbances in the G6PD-deficient population. The gastrointestinal tract, constantly exposed to a diverse microbial milieu, relies on a tightly regulated oxidative balance to maintain mucosal integrity and immune surveillance. The compromised redox environment resulting from G6PD deficiency may perturb gut epithelial barrier function, potentially facilitating increased susceptibility to bacterial and parasitic infections. Moreover, this vulnerability could intertwine with nutritional deficits exacerbated by chronic gastrointestinal illness, underscoring the multifaceted ramifications of this enzymatic anomaly.

Beyond infectious diseases, the research illuminated a nuanced association between G6PD deficiency and the prevalence of certain inflammatory and autoimmune conditions in children. While the exact causal pathways remain to be fully delineated, the study posits that chronic oxidative stress might induce aberrant immune signaling cascades, fostering a milieu conducive to autoimmunity. Emerging data from gene expression analyses support this notion, revealing dysregulated expression of cytokines and regulatory proteins in G6PD-deficient individuals, which could disrupt immune homeostasis. Such revelations open new avenues for exploring therapeutic interventions that target oxidative pathways in mitigating pediatric autoimmune diseases.

Perhaps most compellingly, the study ventured into uncharted territory by investigating G6PD deficiency’s potential impact on neurodevelopmental disorders. The brain’s high oxidative metabolic demand renders it particularly vulnerable to redox imbalances, and mounting evidence implicates oxidative stress as a contributing factor in neurodevelopmental pathologies. Preliminary findings from the study indicated subtle but notable correlations between G6PD deficiency and increased risk markers for conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). These associative trends warrant further exploration but underscore the profound systemic influence that a single enzymatic defect may exert.

Importantly, Liang and colleagues emphasized the variability of G6PD expression and its phenotypic consequences, highlighting heterogeneity in clinical presentations among affected children. Genetic polymorphisms, environmental exposures, and epigenetic modifications likely modulate the severity and spectrum of disease susceptibility, reinforcing the need for personalized approaches in both diagnosis and treatment. This complexity challenges clinicians to refine screening protocols and adopt holistic care paradigms that account for the diverse manifestations of G6PD deficiency.

The study also extended its analysis to the impact of G6PD deficiency on vaccine responsiveness, an area of critical public health relevance. Preliminary data suggested that children with this enzymatic deficiency may exhibit attenuated immunogenicity to certain vaccines, potentially owing to impaired oxidative burst mechanisms required for effective antigen processing and presentation. If substantiated by additional studies, these findings could necessitate tailored vaccination strategies or adjunctive therapies to ensure optimal protection in this vulnerable group.

The epidemiological breadth of the research cannot be overstated. Conducted across multiple pediatric centers with ethnically and geographically diverse populations, the data underscore the global importance of accounting for G6PD deficiency in pediatric disease management strategies. Particularly in regions with a high prevalence of this genetic condition, such as parts of Africa, the Mediterranean, and Southeast Asia, the implications for healthcare policy and resource allocation are profound.

Technological advances in high-throughput sequencing and metabolomics featured prominently in the study’s methodological arsenal. These tools enabled investigators to uncover subtle shifts in metabolic pathways and identify biomarkers predictive of disease susceptibility or progression in G6PD-deficient children. This systems biology approach represents a paradigm shift from traditional single-factor analyses, facilitating a more holistic understanding of how enzymatic defects reverberate through cellular and systemic networks.

Moreover, by integrating clinical observations with molecular data, Liang et al. made significant strides toward elucidating the pathophysiological mechanisms underpinning observed epidemiological patterns. This bridging of bench and bedside knowledge paves the way for development of targeted therapeutics that could enhance antioxidant capacity or modulate immune responses to mitigate disease risk in G6PD-deficient children.

The study’s authors also advocate for increased awareness and early screening for G6PD deficiency within pediatric healthcare frameworks. Given the enzyme’s influence on disease susceptibility, proactive identification could inform monitoring strategies and preemptive interventions, potentially attenuating morbidity and improving long-term outcomes. The integration of G6PD status into electronic medical records and clinical decision support tools was proposed as a practical step to facilitate personalized care.

Ethical considerations permeate discussions surrounding genetic testing and tailored interventions. The authors underscore the necessity of culturally sensitive counseling and equitable access to diagnostic services to prevent exacerbation of health disparities. Policies designed to balance privacy, autonomy, and public health benefits will be critical as genetic screening becomes increasingly embedded in pediatric care.

Beyond the immediate clinical implications, this research invites a broader contemplation of how inherited metabolic deficiencies shape childhood health trajectories. It challenges researchers and clinicians alike to transcend organ-specific paradigms and embrace integrative models that capture the dynamic interrelations between genetics, metabolism, immunity, and environment. The study by Liang and colleagues thus stands as a landmark contribution, charting a course toward comprehensive, mechanism-informed approaches to pediatric disease susceptibility grounded in genetic insights.

Future directions illuminated by this work include interventional trials testing antioxidant supplementation or redox-modulating agents in G6PD-deficient cohorts, longitudinal studies tracking neurodevelopmental outcomes, and expanded investigations into vaccine response optimization. Collaborative multinational efforts will be essential to validate findings across diverse populations and translate research into actionable public health initiatives.

In sum, the compelling evidence presented in this large-scale analysis redefines our understanding of G6PD deficiency far beyond its classical hematologic implications. By revealing its nuanced role in modulating childhood vulnerability to infections, inflammatory diseases, autoimmune conditions, and possibly neurodevelopmental disorders, this study opens promising new frontiers for research, diagnosis, and therapeutic innovation. As pediatric healthcare embraces the genomic era, recognizing and addressing the full spectrum of consequences stemming from enzymatic deficiencies such as G6PD stands to transform outcomes for millions of children worldwide.

Subject of Research: The association between Glucose-6-Phosphate Dehydrogenase deficiency and susceptibility to common pediatric diseases.

Article Title: The association analysis between Glucose-6-Phosphate dehydrogenase deficiency and susceptibility to common diseases in children.

Article References:

Liang, DF., Li, X., Guo, WL. et al. The association analysis between Glucose-6-Phosphate dehydrogenase deficiency and susceptibility to common diseases in children.
Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04148-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04148-0